Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1999;100:II-361-II-364

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Canty, T. G.
Right arrow Articles by Pohlman, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Canty, T. G., Jr
Right arrow Articles by Pohlman, T. H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Cardiomyopathy
Related Collections
Right arrow Oxidant stress
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Gene expression

(Circulation. 1999;100:II-361.)
© 1999 American Heart Association, Inc.


Myocardial Protection and Vascular Biology

Oxidative Stress Induces NF-{kappa}B Nuclear Translocation Without Degradation of I{kappa}B{alpha}

Timothy G. Canty, Jr, MD; Edward M. Boyle, Jr, MD; Angie Farr, BS; Elizabeth N. Morgan, MD; Edward D. Verrier, MD; Timothy H. Pohlman, MD

From the Department of Surgery, University of Washington, Seattle.

Correspondence to Timothy H. Pohlman, Department of Surgery, University of Washington, Harborview Medical Center, Box 359796, Seattle, WA 98104-2924. E-mail tpohlman{at}u.washington.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Background—Rel/NF-{kappa}B, an oxidative stress–responsive transcription factor, participates transiently in the control of gene expression. The cellular mechanisms that mediate NF-{kappa}B activation during ischemia (and during reperfusion in the course of treating ischemia) are not known.

Methods and Results—To investigate the NF-{kappa}B activation induced during oxidative stress, we examined human cardiac tissue obtained during surgical procedures requiring cardiopulmonary bypass. In vitro, we examined human umbilical vein endothelial cells (HUVECs) exposed to hypoxia, reoxygenation after hypoxia, or a reactive oxygen intermediate (H2O2). Electrophoretic mobility shift assays performed on right atrial tissue revealed prominent NF-{kappa}B activation after hearts had been exposed to ischemia and reperfusion. The assays also showed that NF-{kappa}B activation was observed in hypoxic HUVECs after reoxygenation and in cultures treated with H2O2 (500 µmol/L). Pervanadate (200 µmol/L) also induced marked NF-{kappa}B activation in HUVECs, indicating that H2O2-induced NF-{kappa}B activation is potentiated by the inhibition of tyrosine phosphatases. Western blotting of cytoplasmic I{kappa}B{alpha} demonstrated that NF-{kappa}B activation induced by oxidative stress was not associated with I{kappa}B{alpha} degradation. In contrast, tumor necrosis factor-{alpha}–induced NF-{kappa}B activation occurred in concert with degradation of I{kappa}B{alpha}. Inhibition of I{kappa}B{alpha} degradation with a proteasome inhibitor, MG-115, blocked NF-{kappa}B activation induced by tumor necrosis factor-{alpha}; however, MG-115 had no effect on NF-{kappa}B activation during oxidative stress.

Conclusions—This study demonstrated a stimulus-specific mechanism of NF-{kappa}B activation in endothelial cells that acts independently of I{kappa}B{alpha} degradation and may require tyrosine phosphorylation.


Key Words: cardiopulmonary bypass • ischemia • reperfusion • endothelium


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMethods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Reperfusion of ischemic tissue creates a pathophysiological paradox: although reperfusion is necessary to prevent further ischemic necrosis, it may damage or cause dysfunction in otherwise viable tissue; this is referred to as ischemia-reperfusion (I/R) injury.1 I/R injury contributes significantly to morbidity and mortality in patients with ischemic heart disease, stroke, peripheral vascular insufficiency, early transplant organ dysfunction, and hemorrhagic shock. On a cellular level, the reperfusion of ischemic tissue creates oxidative stress.

During reperfusion, endothelial cells are critical in recruiting and activating neutrophils, the principal cause of acute inflammation.2 In response to septic insults, endothelial cells undergo a phenotypic change leading to the synthesis of neutrophil adhesion molecules (eg, E-selectin [CD62E]) and neutrophil chemotactic agents (eg, interleukin [IL]-8).3 4 This transient transcriptional response is mediated, in part, by Rel/nuclear factor {kappa}B (NF-{kappa}B).5 In quiescent endothelium, NF-{kappa}B is held inactive within the cytoplasm by interaction with inhibitor {kappa}B (I{kappa}B{alpha}) or other I{kappa}B family members.6 After stimulation with tumor necrosis factor (TNF)-{alpha}, lipopolysaccharide (LPS), or IL-1, I{kappa}B{alpha} undergoes rapid phosphorylation on serine residues 32 and 36; this signals the proteolytic degradation of I{kappa}B{alpha} in proteasomes.7 The dissociation of I{kappa}B{alpha} from NF-{kappa}B exposes the nuclear localization signal8 on NF-{kappa}B, which directs the translocation of the transcription factor to the nucleus to promote the expression of genes that mediate inflammatory reactions.9 NF-{kappa}B–mediated regulation of inflammatory gene expression in human endothelial cells during oxidative stress, however, is not defined.

In this study, we demonstrated that NF-{kappa}B activation occurs in human hearts subjected to ischemia and reperfusion during surgical procedures using cardiopulmonary bypass. In addition, we showed in vitro that NF-{kappa}B activation occurs in cultured human endothelial cells treated with a reactive oxygen intermediate (H2O2) and in cultures exposed to hypoxia followed by reoxygenation. Unlike NF-{kappa}B activation induced by TNF-{alpha}, IL-l, or LPS, NF-{kappa}B activation under conditions of oxidative stress is achieved without measurable degradation of I{kappa}B{alpha} and may involve tyrosine phosphorylation.


*    Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were obtained by collagenase (Worthington Biochemical) digestion, as previously described.10 Cultures were maintained in RPMI 1640 solution (Whittaker) supplemented with 20% adult bovine serum (JRH Biosciences), 90 U/mL heparin (Sigma), 50 U/mL endothelial cell growth supplement (Collaborative Research), and 1% antibiotics in room air at 37°C. HUVECs were serially passaged by brief exposure to Versene (GIBCO/BRL) and 0.05% trypsin with EDTA (GIBCO/BRL). Third-passage confluent HUVEC monolayers were used in all experiments.

Human Cardiac Tissue Procurement
Right auricular tissue from patients undergoing coronary artery bypass grafting was obtained during cannulation of the right atrium in preparation for cardiopulmonary bypass (CPB). Skeletal muscle samples were obtained from the intercostal muscle. Samples were obtained before the start of cardioplegia and cardiac arrest and 45 minutes after the patient was taken off bypass. All tissues were immediately snap-frozen in liquid nitrogen in the operating room. Frozen tissue samples, 0.25 to 0.5 g, were then ground to a fine powder and suspended in 4.0 mL of buffer containing 0.06% Nonidet P-40, 150 mmol/L NaCl, 10 mmol/L HEPES, 1 mmol/L EDTA, and 0.5 mmol/L PMSF. The solution was then homogenized and centrifuged for 15 s. The pellet was discarded, and the supernatant was cooled to 4°C. The supernatant was then centrifuged again for 15 s. The pellet was resuspended in 40 µL of buffer containing (in mmol/L): NaCl 420, HEPES 20, EDTA 0.2, MgCl2 1.2, PMSF 0.5, and DDT 0.5 and 25% glycerol, 5 µg/mL aprotinin, and 5 µg/mL leupeptin at 4°C for 20 minutes. This solution was then centrifuged for 5 minutes, the pellet was discarded, and the supernatant, containing nuclear proteins, was frozen at -70°C. Samples were analyzed for NF-{kappa}B as described below. This study was approved by the Human Subjects Committee of the University of Washington.

Hypoxia and Reoxygenation
Normoxic control cells were maintained at 37°C in a standard incubator at room air oxygen tension (21% oxygen; designated normoxia). To expose HUVECs to hypoxia, cultures were placed in a controlled environmental chamber (Coy Laboratory Products) at 37°C and maintained at an oxygen tension of 2% to 3%. Oxygen content in the media over HUVECs equilibrated with the hypoxic environment of the chamber within 10 minutes, as measured by a Clark electrode (data not shown). To expose HUVECs to hypoxia and reoxygenation, cultures were removed from the hypoxia chamber and placed in a normoxic incubator for designated periods of time.

Electrophoretic Mobility Shift Assay
Third-passage HUVEC monolayers in 100-mm2 plates were exposed to 2 hours of hypoxia followed by reoxygenation, H2O2 (100 to 500 µmol/L), pervanadate (100 to 200 µmol/L), or TNF-{alpha} (100 U/mL) for designated time periods. Nuclear protein extractions were performed using a modification of the technique of Dignam et al,10A as previously described.11 Approximately 10 µg of nuclear protein was incubated in a binding reaction with a double-stranded, 32P-end-labeled oligonucleotide containing the human consensus NF-{kappa}B binding sequence 5'-GCCATTGGGGATTTCCTCTTTACTGG-3' (Promega). Binding reactions occurred at room temperature for 20 minutes. Proteins were resolved on 6% nondenaturing polyacrylamide gels at 100 V for 1 to 2 hours in a 0.5% Tris-boric acid-EDTA solution. The gels were dried and autoradiographed.

Western Blot Analysis
Confluent HUVEC monolayers on 100-mm2 plates were treated with conditions of oxidative stress or TNF-{alpha} in the manner described above. Cytoplasmic extracts were obtained using a modified lysis buffer,5 and total protein concentration was determined using a standard protein assay. Approximately 20 µg of protein was loaded on SDS-PAGE gels and resolved at 100 V for 2 hours. After transfer to a polyvinylidene difluoride membrane, the membrane was stained with Coomassie blue to determine equal protein transfer. The membranes were then incubated with anti-I{kappa}B{alpha} polyclonal antibody (Santa Cruz Biotechnology) at 1:1000 dilution for 2 hours. A HRP-conjugated secondary antibody was applied for 1 hour, and the proteins were visualized using Amersham enhanced chemiluminescent reagents and autoradiography.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
*Results
down arrowDiscussion
down arrowReferences
 
To determine the activation of NF-{kappa}B in human tissue under conditions of oxidative stress, cardiac and skeletal muscle samples were acquired before patients were placed on CPB and after reperfusion of the heart for 45 minutes, after the patient was taken off CPB. We chose right atrial tissue because this tissue receives the least amount of cardioplegia during CPB, and the anterior location of the right atrium makes it less likely to be cooled to a temperature approaching 4°C; previously, we demonstrated that NF-{kappa}B can be activated at temperatures lower than 37°C but not at those <=4°C.12 As shown in Figure 1Down, NF-{kappa}B was prominently activated in human atrial tissue after 45 minutes of reperfusion of the ischemic heart. However, skeletal muscle obtained from the same patient at the same time points but not exposed to ischemia and reperfusion showed no evidence of NF-{kappa}B activation.



View larger version (70K):
[in this window]
[in a new window]
 
Figure 1. NF-{kappa}B is activated in reperfused human heart tissue. Right atrial tissue was obtained from hearts of patients during cannulation of right atrium in preparation for CPB (Pre-CPB) and 45 minutes after discontinuation of CPB (Post-CPB). Matched skeletal muscle tissue was obtained from same patient at same times atrial tissue samples were procured. Excised tissue was immediately placed in liquid N2 (-70°C) and processed for NF-{kappa}B assays, as described in Methods. Results for 1 patient are shown; similar results were obtained in 4 other patients.

To define more specifically mechanisms of oxidative stress–induced NF-{kappa}B activation, HUVECs were reoxygenated after a 2-hour period of hypoxia and treated with H2O2 or pervanadate. Also, HUVECs were treated with medium alone or medium containing TNF-{alpha} (100 U/mL) for 2 hours as a control stimulus of NF-{kappa}B activation. In each experiment, either nuclear proteins were extracted for electrophoretic mobility shift assays (EMSAs) to determine NF-{kappa}B activation or cytoplasmic proteins were extracted for Western blotting to determine the presence or absence of I{kappa}B{alpha}. As shown in Figure 2ADown, TNF-{alpha} induced rapid degradation of I{kappa}B{alpha} protein, with concomitant nuclear translocation of NF-{kappa}B within 5 to 10 minutes of the addition of TNF-{alpha}; complete I{kappa}B{alpha} degradation was noted by 15 minutes, with the reappearance of I{kappa}B{alpha} in the cytoplasm by 1 hour during continuous exposure to TNF-{alpha}. Similar results were obtained when cells were treated with IL-1 (10 U/mL) or LPS (100 ng/mL) (data not shown). HUVECs exposed to 2 hours of hypoxia followed by reoxygenation for various periods of time also demonstrated rapid nuclear translocation of NF-{kappa}B within 15 minutes after reoxygenation was started (Figure 2BDown). Similarly, rapid nuclear translocation of NF-{kappa}B occurred in HUVECs treated with H2O2 (Figure 2CDown). However, in contrast to the treatment of HUVECs with TNF-{alpha}, reoxygenation of hypoxic HUVECs (Figure 2BDown) and treatment of HUVECs with H2O2 (Figure 2CDown) did not result in degradation of I{kappa}B{alpha}.



View larger version (31K):
[in this window]
[in a new window]
 
Figure 2. NF-{kappa}B is activated by oxidative stress without I{kappa}B{alpha} degradation. A, HUVECs were exposed to medium alone or medium containing TNF-{alpha} (100 U/mL) for variable periods of time (min), which are indicated across top panel. At end of each time period, cytoplasmic proteins were assayed by Western blot for I{kappa}B{alpha} (top panel) or nuclear proteins were assayed by EMSA for NF-{kappa}B nuclear translocation (bottom panel). B, HUVEC monolayers were exposed to hypoxia (partial pressure of O2, 2% to 3%) for 2 hours. At end of 2-hour hypoxia-incubation period, HUVECs were reoxygenated (partial pressure of O2, 21%) for variable periods of time. At end of each reoxygenation period, cytoplasmic proteins and nuclear proteins were assayed by Western blotting for I{kappa}B{alpha} (top panel) or by EMSA for NF-{kappa}B translocation (lower panel), respectively. C, HUVECs were treated with medium alone or medium containing freshly diluted H2O2 (500 µmol/L, final concentration) for variable periods of time. Cytoplasmic proteins and nuclear proteins were assayed at each time point for I{kappa}B{alpha} (top panel) and NF-{kappa}B (lower panel), as described in A. D, HUVECs were treated with medium alone or medium containing pervanadate (200 µmol/L), which was prepared fresh just before addition to tissue-culture plates. I{kappa}B{alpha} (top panel) and NF-{kappa}B (lower panel) were determined at end of incubation periods indicated across top panel. For each condition, experiments were repeated at least 4 separate times with HUVECs that were harvested from different umbilical cords each time.

Tyrosine phosphorylation of I{kappa}B{alpha} in Jurkat T-cells treated with pervanadate reportedly prevents I{kappa}B{alpha} degradation.13 Pervanadate, a tyrosine phosphatase inhibitor, is composed of H2O2 and vanadate. Pervanadate thus preserves transient tyrosine phosphorylation of proteins and potentiates signal transduction pathways involving tyrosine kinases. As shown in Figure 2DUp, pervanadate treatment initiated rapid and pronounced nuclear translocation of NF-{kappa}B, without associated degradation of I{kappa}B{alpha}. To exclude the possibility that oxidative stress induces NF-{kappa}B activation through the degradation of NF-{kappa}B cytoplasmic inhibitors other than I{kappa}B{alpha}, Western blots (using polyclonal antisera to I{kappa}B family members I{kappa}Bß or I{kappa}B{epsilon}) were performed on cytoplasmic proteins from HUVECs treated with pervanadate. Neither I{kappa}Bß nor I{kappa}B{epsilon} were degraded in HUVECs exposed to oxidative stress (data not shown).

Because oxidative stress seems to activate NF-{kappa}B without apparent degradation of I{kappa}B proteins, we reasoned that inhibitors of I{kappa}B degradation in the proteasome should have no effect on oxidative stress-induced NF-{kappa}B activation. To test this hypothesis, proteasome function in HUVECs was inhibited with the peptide aldehydes MG 115 or N-acetyl-leucine-leucine-not leucine (ALLN).14 15 As shown in Figure 3ADown, MG 115 (30 µmol/L) predictably blocked TNF-{alpha}–induced activation of NF-{kappa}B; it had no effect, however, on NF-{kappa}B activation in response to oxidative stress in HUVECs treated with pervanadate. Identical results were obtained with ALLN (data not shown; 4 separate experiments). These results further support the possibility that oxidative stress-induced NF-{kappa}B translocation to the nucleus can occur independently of I{kappa}B degradation, suggesting that alternate pathways of NF-{kappa}B activation exist in cardiovascular cells sustaining I/R injury.



View larger version (22K):
[in this window]
[in a new window]
 
Figure 3. Proteasome inhibition does not block oxidative stress–induced NF-{kappa}B activation. HUVECs were treated with medium alone or medium containing either (A) TNF-{alpha} (100 U/mL) or (B) pervanadate (200 µmol/L), both for 2 hours, in presence or absence of MG 115 (30 µmol/L). After 2 hours, nuclear proteins were isolated and assayed for NF-{kappa}B by EMSA, as described in Methods. Results shown are representative of 4 similar experiments with MG 115.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
*Discussion
down arrowReferences
 
Endothelial cell activation is mediated through NF-{kappa}B in response to diverse stimuli. It is unknown, however, whether each stimulus activates NF-{kappa}B through the same signaling pathway or through different and unique pathways. Our findings indicate that in HUVECs, oxidative stress activates NF-{kappa}B through a mechanism that does not require I{kappa}B{alpha} degradation, a biochemical event that is required for TNF-{alpha}–induced NF-{kappa}B activation. I{kappa} or I{kappa}B{epsilon} degradation, as measured by Western blot analysis with polyclonal antibodies specific for each inhibitor protein, also was not observed in HUVECs exposed to oxidative stress (data not shown). Although not degraded, I{kappa}B is most likely modified in some fashion during oxidative stress to cause I{kappa}B to dissociate from NF-{kappa}B, exposing a nuclear localization signal in NF-{kappa}B as a prerequisite to nuclear translocation of NF-{kappa}B.8 This conjecture, however, was not examined in the present study.

TNF-{alpha} stimulation of HUVECs results in rapid phosphorylation of I{kappa}B{alpha} serine residues 32 and 36 by a multimeric I{kappa}B kinase complex, which is activated by other upstream kinases.7 16 Serine phosphorylation of I{kappa}B{alpha} is followed by addition of a ubiquitin protein to I{kappa}B{alpha} and degradation in the proteasome.7 Recent reports have demonstrated that I{kappa}B can also be phosphorylated on a tyrosine residue at position 42 of I{kappa}B{alpha}, which is in close proximity to the 2 serine phosphoacceptor sites.13 17 Tyrosine-phosphorylated I{kappa}B{alpha} is protected from TNF-{alpha}–induced degradation, although the mechanism of this protective effect is not known. In Jurkat T-cells, tyrosine phosphorylation of I{kappa}B{alpha} is observed after exposure of this cell line to pervanadate or to hypoxia followed by reoxygenation, and tyrosine phosphorylation produces dissociation of tyrosine-phosphorylated I{kappa}B{alpha} from NF-{kappa}B.18 Tyrosine phosphorylation of I{kappa}B{alpha} in Jurkat T-cells after exposure to hypoxia only has been observed as well.19 In the study with hypoxic Jurkat T-cells, I{kappa}B{alpha} degradation was observed 60 minutes after the onset of hypoxia. In contrast, we did not observe I{kappa}B{alpha} degradation in HUVECs after 60 minutes of hypoxia. Moreover, NF-{kappa}B activation in hypoxic HUVECs occurs within 15 minutes of the onset of reoxygenation of hypoxic cells. Therefore, we are unable to relate the response of Jurkat T-cells to hypoxia to the human endothelial cell activation induced by oxidative stress.

The results we obtained in vitro may be relevant to I/R injury in vivo. In patients undergoing open heart surgery, we assayed right atrial tissue samples for NF-{kappa}B activation. Tissue was obtained before CPB and 45 minutes after CPB was discontinued. We showed that NF-{kappa}B is activated in human hearts reperfused for 45 minutes after the discontinuation of CPB, but not in skeletal muscle samples that were continuously perfused and oxygenated. This is the first demonstration of NF-{kappa}B in vivo in human hearts with I/R injury.

In summary, our results suggest that oxidative stress in human vascular cells may activate the proinflammatory transcription factor NF-{kappa}B through an alternative pathway independent of I{kappa}B{alpha} degradation. Thus, the inflammatory response to oxidative stress involving NF-{kappa}B and occurring during I/R injury may be inhibited without compromising a cytokine-induced, NF-{kappa}B–mediated inflammatory response to infection.


*    Acknowledgments
 
The authors thank Dr Jeanette Griscavage-Ennis for her critical review of the manuscript and Ellen Collins for her expert technical assistance.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMethods
up arrowResults
up arrowDiscussion
*References
 

  1. Boyle EM Jr, Pohlman TH, Cornejo CJ, Verrier ED. Endothelial cell injury in cardiovascular surgery: ischemia reperfusion. Ann Thorac Surg. 1996;62:1868–1875.[Abstract/Free Full Text]
  2. Winn RK, Liggitt D, Vedder NB, Paulson JC, Harlan JM. Anti-P-selectin monoclonal antibody attenuates reperfusion injury to the rabbit ear. J Clin Invest. 1993;92:2042–2047.
  3. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation. 1990;50:537–544.[Medline] [Order article via Infotrieve]
  4. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev. 1990;70:427–451.[Free Full Text]
  5. Read MA, Whitley MZ, Williams AJ, Collins T. NF-{kappa}B and I{kappa}B{alpha}: an inducible regulatory system in endothelial activation. J Exp Med. 1994;179:503–512.[Abstract/Free Full Text]
  6. Beg AA, Baldwin AS Jr. The I{kappa}B proteins: multifunctional regulators of Rel/NF-{kappa}B transcription factors. Genes Dev. 1993;7:2064–2070.[Free Full Text]
  7. Brown K, Gerstberger S, Carlson L, Franzoso G, Siebenlist U. Control of I{kappa}B{alpha} proteolysis by site specific, signal induced phosphorylation. Science. 1995;267:1485–1488.[Abstract/Free Full Text]
  8. Jans DA, Hubner S. Regulation of protein transport to the nucleus: central role of phosphorylation. Physiol Rev. 1996;76:651–685.[Abstract/Free Full Text]
  9. Baeuerle PA, Baltimore D. NF-{kappa}B: 10 years after. Cell. 1996;87:13–20.[Medline] [Order article via Infotrieve]
  10. Magnuson DK, Weintraub A, Pohlman TH, Maier RV. Human endothelial cell adhesiveness for neutrophils, induced by Escherichia coli lipopolysaccharide in vitro, is inhibited by Bacteroides fragilis lipopolysaccharide. J Immunol. 1989;143:3025–3030.[Abstract]
  11. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiated by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 1983;11:1475–1489.
  12. Montgomery KF, Osborn L, Hession C, Tizard R, Goff D, Vassallo C, Tarr PI, Bomsztyk K, Lobb R, Harlan JM, Pohlman TH. Activation of endothelial-leukocyte adhesion molecule 1 (ELAM-1) gene transcription. Proc Natl Acad Sci U S A. 1991;88:6523–6527.[Abstract/Free Full Text]
  13. Haddix TL, Pohlman TH, Noel RF, Sato TT, Boyle EM Jr, Verrier ED. Hypothermia inhibits human E-selectin transcription. J Surg Res. 1996;64:176–183.[Medline] [Order article via Infotrieve]
  14. Singh S, Darnay BG, Aggarwal BB. Site-specific tyrosine phosphorylation of I{kappa}B{alpha} negatively regulates its inducible phosphorylation and degradation. J Biol Chem. 1996;271:31049–31054.[Abstract/Free Full Text]
  15. Zen K, Karsan A, Eunson T, Yee E, Harlan JM. Lipopolysaccharide-induced NF-{kappa}B activation in human endothelial cells involves degradation of I{kappa}B{alpha} but not I{kappa}Bß. Exp Cell Res. 1998;243:425–433.[Medline] [Order article via Infotrieve]
  16. Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Brenner DA. Inhibition of NF-{kappa}B in activated rat hepatic stellate cells by proteasome inhibitors and an I{kappa}B super-repressor. Hepatology. 1998;27:1285–1295.[Medline] [Order article via Infotrieve]
  17. Traenckner EB, Pahl HL, Henkel T, Schmidt KN, Wilk S, Baeuerle PA. Phosphorylation of human I{kappa}B{alpha} on serines 32 and 36 controls I{kappa}B{alpha} proteolysis and NF-{kappa}B activation in response to diverse stimuli. EMBO J. 1995;14:2876–2883.[Medline] [Order article via Infotrieve]
  18. Abu-Amer Y, Ross FP, McHugh KP, Livolsi A, Peyron JF, Teitelbaum SL. Tumor necrosis factor-{alpha} activation of nuclear transcription factor-{kappa}B in marrow macrophages is mediated by c-Src tyrosine phosphorylation of I{kappa}B{alpha}. J Biol Chem. 1998;273:29417–29423.[Abstract/Free Full Text]
  19. Imbert V, Rupec RA, Livolsi A, Pahl HL, Traenckner EB, Mueller-Dieckmann C, Farahifar D, Rossi B, Auberger P, Baeuerle PA, Peyron JF. Tyrosine phosphorylation of I{kappa}B{alpha} activates NF-{kappa}B without proteolytic degradation of I{kappa}B{alpha}. Cell. 1996;86:787–798.[Medline] [Order article via Infotrieve]
  20. Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of nuclear factor {kappa}B through the phosphorylation of I{kappa}B{alpha} on tyrosine residues. Cancer Res. 1994;54:1425–1430.[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Canty, T. G.
Right arrow Articles by Pohlman, T. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Canty, T. G., Jr
Right arrow Articles by Pohlman, T. H.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Cardiomyopathy
Related Collections
Right arrow Oxidant stress
Right arrow Endothelium/vascular type/nitric oxide
Right arrow Gene expression